NCT05548088 - LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

August 3, 2024

Study Completion Date

August 3, 2024

Conditions

Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia

Interventions

BIOLOGICAL

LILRB4 STAR-T cells

Subjects with relapsed/refractory acute myeloid leukemia will be enrolled in the study, and Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4and-3followed by infusion of STAR-T cells. STAR-T cells will be intravenously infused with a escalated dose of 1E6,3E6,6E6,1E7 cells/kg

Trial Locations (2)

100044

Peking Unicersity People'S Hospital, Beijing

Peking University People's Hospital, Beijing

All Listed Sponsors

collaborator

Bristar Immunotech Limited

UNKNOWN

lead

Peking University People's Hospital

OTHER